|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2004-10-25
|
|
pubmed:abstractText |
UCN-01 (7-hydroxystaurosporine) is a small molecule cyclin-dependent kinase modulator currently under clinical development as an anticancer agent. In vitro studies have demonstrated that UCN-01 is strongly bound to the acute-phase reactant alpha (1)-acid glycoprotein (AAG). Here, we examined the role of protein binding as a determinant of the pharmacokinetic behavior of UCN-01 in patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AcharyaMilin RMR,
pubmed-author:ChenHuachenH,
pubmed-author:FiggWilliam DWD,
pubmed-author:HeadleeDonnaD,
pubmed-author:KuwabaraTakashiT,
pubmed-author:MessmannRichard ARA,
pubmed-author:MurgoAnthony JAJ,
pubmed-author:SausvilleEdward AEA,
pubmed-author:SenderowiczAdrian MAM,
pubmed-author:SparreboomAlexA,
pubmed-author:VenzonDavid JDJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6840-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
|
|
pubmed:affiliation |
Clinical Pharmacology Research Core, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
